Skip to content
DeepViews

Teva Pharmaceutical Industries Limited (TEVA) — Analysis Summary

Teva Pharmaceutical Industries Limited (TEVA) has a market cap of $48.02B with year-over-year revenue growth of +4.3%. Net margin stands at 8.2%. The stock trades at a P/E ratio of 68.0.

Key Takeaways

  • Revenue changed +4.3% year-over-year
  • Net margin of 8.2%
  • P/E ratio of 68.0

Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, TEVA posted revenue growth of +4.3% and trades at a P/E of 68.0.

[XNYS]

Teva Pharmaceutical Industries Limited (TEVA)

$41.17

PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR

Market Cap
$48.02B
Enterprise Value
$48.86B
P/E Ratio
68.0
Div Yield
0.83%
EV/EBITDA
18.9
Company Profile
About
About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Sector

PHARMACEUTICAL PREPARATIONS

Employees

32,842

Headquarters

TEL AVIV

Exchange

XNYS

Website
Source: Polygon.io
Score
Competitive Moat
Competitive Moat
55
Narrow Moat

Systematic competitive advantage assessment based on 4yr data

This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.

Market Signals
Valuation
Earnings
Insider Activity
Insider Filing Activity

First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.

Loading SEC insider filing activity...
Superinvestors
Financial Health
Financial Health

Capital Structure

Total Equity$7757.00M
Total Debt$4500.00M
Debt-to-Equity0.58
Cash & Equivalents$3655.00M

Cash Flow

Operating Cash Flow$1898.00M
Free Cash Flow$1347.00M
FCF Margin7.78%
P/FCF Ratio35.65
Source: Polygon.io · SEC EDGAR
Dividends
Dividends

Annual Dividend/Share

$0.34

Dividend Yield

0.83%

Quarterly
Last Ex-Date: 2017-11-27

Dividend History

2017-11-27
CD$0.0850
2017-08-25
CD$0.0850
2017-06-01
CD$0.3400
2017-02-28
CD$0.3400
Source: Polygon.io
Recent News
Recent News

Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.